Squarepoint
HUMA icon

Squarepoint’s Humacyte HUMA Stock Holding History

Squarepoint’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-458,178
Closed -$440K – 4559
2025
Q4 		$440K Buy
+458,178
New +$649K ﹤0.01% 3313
2025
Q3 		– Sell
-238,236
Closed -$498K – 4621
2025
Q2 		$498K Buy
+238,236
New +$458K ﹤0.01% 3286
2025
Q1 		– Sell
-26,098
Closed -$132K – 4948
2024
Q4 		$132K Buy
+26,098
New +$129K ﹤0.01% 4622
2024
Q3 		– Sell
-68,319
Closed -$328K – 4354
2024
Q2 		$328K Sell
68,319
-23,661
-26% -$123K ﹤0.01% 3372
2024
Q1 		$286K Buy
+91,980
New +$309K ﹤0.01% 3429
2022
Q2 		– Sell
-59,531
Closed -$420K – 3083
2022
Q1 		$420K Buy
+59,531
New +$347K ﹤0.01% 2108

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Squarepoint's HUMA Position: Q1 2026 in Review

Squarepoint sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 458,178 shares — an estimated $440K sold.

Squarepoint first reported a position in HUMA in Q1 2022 and held it in 6 quarters. The position peaked at $498K in Q2 2025. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Squarepoint reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 458,178 Humacyte shares in Q1 2026, an estimated $440K.
  • Squarepoint first reported a position in Humacyte in Q1 2022 and held it in 6 quarters.
  • Squarepoint's Humacyte position peaked at $498K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.